About Us

We address the underlying causes of ophthalmic diseases

Enhancing Lives & Better Vision

Okogen is an ophthalmic specialty pharmaceutical company focused on developing the leading treatment for both bacterial and viral conjunctivitis.

Our lead product candidate, OKG-0303, is being developed to treat infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial agent.

There are 6 million new cases of acute conjunctivitis per year in United States.

Meet the Team

Meet the Team

Management

Bradford A. Conlan

Executive Chairman and CEO

Bradford A. Conlan

Executive Chairman and CEO

Mr. Conlan is a co-founder of Okogen, Inc. He is also a co-founder of Bayon Therapeutics (Acquired by Kiora Pharmaceuticals, NASDAQ: KPRX) and Bimini Health Tech where he has served as CEO and board member since 2013.

Mr. Conlan has over 18 years of experience in biotechnology, pharmaceutical and medical devices as an engineer, scientist, entrepreneur and investor. He received a B.S. in Biomedical and Industrial Engineering from the University of Iowa and an M.S. in Biomedical Engineering from the University of Southern California.

Read More

Joshua H. Moriarty

Chief Operating Officer and Board Member

Joshua H Moriarty

Chief Executive Officer

Joshua H Moriarty is the Chief Executive Officer of Okogen, Inc. Joshua has spent 17 years in ophthalmic product development, most recently as Executive Director at Ora, Inc. working alongside small to mid-size ophthalmic companies traversing the development process.

Joshua received his Bachelor of Arts from the University of Massachusetts and is the proud father of 2 daughters.

Read More

Board of Directors

Brian M Strem, PhD

Brian M Strem, PhD

Brian M Strem, PhD is a co-founder of Okogen Inc and current President & CEO of Kiora Pharmaceuticals (NASDAQ:KPRX). Previously, Brian worked at Sound Pharmaceuticals, Allergan and Shire, responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments.

Brian received his BS in bioengineering from Cornell University and his PhD in biomedical engineering from UCLA.

Read More

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA is a Co-Founder of Okogen and is currently the Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX). Eric has nearly 20 years of operating experience in biotechnology and medtech companies, including Tensys Medical, Kerastem, and Cytori Therapeutics, where he has held leadership roles within the commercial, medical and R&D organizations.

Eric holds a Masters of Business Administration from the Anderson School of Management at the University of California, Los Angeles. He received his Doctor of Medicine degree from the University of California, Los Angeles School of Medicine and his undergraduate degree in Molecular Biology from the University of California, Berkeley.

Read More

Quinton Oswald

Quinton Oswald

Quinton Oswald was the CEO of Notal Vision, a cloud based telemedicine company driven by AI tools. Prior to that, he served as CEO of Neurotech Pharmaceuticals and SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra™) for the treatment of dry eye disease (sold to Shire, PLC).

Previously, he served as the Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business, where he also oversaw the  commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Quinton led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Russel Van Gelder, MD, PhD

Stephanie Watson, MD

Latest News & Press

View All News
Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022
Read More
Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021
Read More
Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019
Read More

© 2023 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS

Main Menu